Catalog No.: PC-22085Not For Human Use, Lab Use Only.
JPC-141 is a potent, selective vesicular monoamine transporter-2 (VMAT2) inhibitor, potently inhibits [3H]dopamine uptake by VMAT2 in striatal vesicles with Ki of 52 nM.
JPC-141 is a potent, selective vesicular monoamine transporter-2 (VMAT2) inhibitor, potently inhibits [3H]dopamine uptake by VMAT2 in striatal vesicles with Ki of 52 nM.
JPC-141 displays 50 to 250-fold greater selectivity for VMAT2 over dopamine, norepinephrine and serotonin plasmalemma transporters.
JPC-141 is 57-fold more selective for inhibiting VMAT2 over [3H]dofetilide binding to hERG channels expressed by HEK293.
JPC-141 prevents the METH-induced reduction in striatal dopamine content in rats.
JPC-141 decreases METH-stimulated locomotor activity in METH-sensitized rats at doses of does not alter locomotor activity in the saline control group.
JPC-141 specifically decreased iv METH self-administration at doses that had no effect on food-maintained responding.
Physicochemical Properties
M.Wt
324.47
Formula
C21H28N2O
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
1-(2-methoxyphenethyl)-4-phenethypiperazine
References
1. Chandler CM, et al. Biochem Pharmacol. 2024 Apr 3:116189.
